• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

B 和辅助性 T 细胞的动态免疫表型标志着 T1D 进展的不同阶段。

Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression.

机构信息

Translational Research Program, Benaroya Research Institute, Seattle, WA.

Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA.

出版信息

Diabetes. 2019 Jun;68(6):1240-1250. doi: 10.2337/db18-1081. Epub 2019 Mar 20.

DOI:10.2337/db18-1081
PMID:30894366
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6610015/
Abstract

Multiple studies of B- and T-cell compartments and their response to stimuli demonstrate alterations in established type 1 diabetes (T1D). Yet it is not known whether these alterations reflect immune mechanisms that initiate islet autoimmunity, promote disease progression, or are secondary to disease. To address these questions, we used samples from the TrialNet Pathway to Prevention study to investigate T-cell responses to interleukin (IL)-2 and regulatory T cell-mediated suppression, the composition of the B-cell compartment, and B-cell responses to B-cell receptor and IL-21 receptor engagement. These studies revealed stage-dependent T- and B-cell functional and immune phenotypes; namely, early features that differentiate autoantibody-positive at-risk first-degree relatives (FDRs) from autoantibody-negative FDRs and persisted through clinical diagnosis; late features that arose at or near T1D diagnosis; and dynamic features that were enhanced early and blunted at later disease stages, indicating evolving responses along the continuum of T1D. We further explored how these specific phenotypes are influenced by therapeutic interventions. Our integrated studies provide unique insights into stable and dynamic stage-specific immune states and define novel immune phenotypes of potential clinical relevance.

摘要

多项针对 B 细胞和 T 细胞区室及其对刺激反应的研究表明,在已建立的 1 型糖尿病 (T1D) 中存在改变。然而,目前尚不清楚这些改变是否反映了启动胰岛自身免疫、促进疾病进展的免疫机制,还是继发于疾病的改变。为了解决这些问题,我们使用来自 TrialNet 预防研究途径的样本,研究了 T 细胞对白细胞介素 (IL)-2 和调节性 T 细胞介导的抑制、B 细胞区室的组成以及 B 细胞对 B 细胞受体和 IL-21 受体结合的反应。这些研究揭示了与疾病进展相关的 T 细胞和 B 细胞功能和免疫表型的阶段依赖性;即,可区分自身抗体阳性的一级亲属 (FDR) 和自身抗体阴性 FDR 的早期特征,并贯穿临床诊断持续存在;在 T1D 诊断时或附近出现的晚期特征;以及早期增强、晚期减弱的动态特征,表明沿着 T1D 连续体的反应不断演变。我们进一步探讨了这些特定表型如何受到治疗干预的影响。我们的综合研究为稳定和动态的特定阶段免疫状态提供了独特的见解,并定义了具有潜在临床相关性的新型免疫表型。

相似文献

1
Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression.B 和辅助性 T 细胞的动态免疫表型标志着 T1D 进展的不同阶段。
Diabetes. 2019 Jun;68(6):1240-1250. doi: 10.2337/db18-1081. Epub 2019 Mar 20.
2
Circulating CXCR5+PD-1+ICOS+ Follicular T Helper Cells Are Increased Close to the Diagnosis of Type 1 Diabetes in Children With Multiple Autoantibodies.在患有多种自身抗体的儿童中,循环CXCR5 + PD-1 + ICOS +滤泡辅助性T细胞在接近1型糖尿病诊断时会增加。
Diabetes. 2017 Feb;66(2):437-447. doi: 10.2337/db16-0714. Epub 2016 Oct 10.
3
FOXP3+ Regulatory T Cell Compartment Is Altered in Children With Newly Diagnosed Type 1 Diabetes but Not in Autoantibody-Positive at-Risk Children.FOXP3+ 调节性 T 细胞在新诊断为 1 型糖尿病的儿童中发生改变,但在自身抗体阳性的高危儿童中未发生改变。
Front Immunol. 2019 Jan 22;10:19. doi: 10.3389/fimmu.2019.00019. eCollection 2019.
4
Defective inducer T-cell function before the onset of insulin-dependent diabetes mellitus.胰岛素依赖型糖尿病发病前诱导性T细胞功能缺陷。
J Autoimmun. 1991 Feb;4(1):125-36. doi: 10.1016/0896-8411(91)90012-2.
5
Predominantly recognized proinsulin T helper cell epitopes in individuals with and without islet cell autoimmunity.在有和没有胰岛细胞自身免疫的个体中主要识别的胰岛素原T辅助细胞表位。
J Autoimmun. 2002 Feb;18(1):55-66. doi: 10.1006/jaut.2001.0566.
6
B cell helper T cells and type 1 diabetes.B 细胞辅助性 T 细胞与 1 型糖尿病。
Scand J Immunol. 2020 Oct;92(4):e12943. doi: 10.1111/sji.12943.
7
Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes.多参数流式细胞术和遗传学分析人类 1 型糖尿病外周 B 细胞区室。
Clin Exp Immunol. 2014 Sep;177(3):571-85. doi: 10.1111/cei.12362.
8
Shortening the paths to type 1 diabetes mellitus prevention.缩短1型糖尿病预防之路。
Nat Rev Endocrinol. 2021 Feb;17(2):73-74. doi: 10.1038/s41574-020-00450-5.
9
miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity.微小RNA92a靶向KLF2和磷酸酶PTEN信号通路,以促进1型糖尿病胰岛自身免疫中的人类辅助性滤泡T细胞前体。
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6659-E6668. doi: 10.1073/pnas.1606646113. Epub 2016 Oct 10.
10
Analyses of regulatory CD4+ CD25+ FOXP3+ T cells and observations from peripheral T cell subpopulation markers during the development of type 1 diabetes in children.儿童1型糖尿病发展过程中调节性CD4+ CD25+ FOXP3+ T细胞的分析及外周血T细胞亚群标志物的观察
Scand J Immunol. 2016 Apr;83(4):279-87. doi: 10.1111/sji.12418.

引用本文的文献

1
Role of EP4 factor in paediatric type 1 diabetes mellitus: a comprehensive review focusing on the honeymoon period.EP4因子在儿童1型糖尿病中的作用:一项聚焦蜜月期的综述
Pediatr Endocrinol Diabetes Metab. 2024;30(4):227-246. doi: 10.5114/pedm.2024.146686.
2
GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes.GNTI-122:一种用于 1 型糖尿病的自体抗原特异性工程化 Treg 细胞疗法。
JCI Insight. 2024 Feb 8;9(6):e171844. doi: 10.1172/jci.insight.171844.
3
Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review.1型糖尿病预防中改善病情的疗法及与治疗反应相关的特征:一项系统评价
Commun Med (Lond). 2023 Oct 5;3(1):130. doi: 10.1038/s43856-023-00357-y.
4
Translational immunology: Applying fundamental discoveries to human health and autoimmune diseases.转化免疫学:将基础发现应用于人类健康和自身免疫性疾病。
Eur J Immunol. 2023 Dec;53(12):e2250197. doi: 10.1002/eji.202250197. Epub 2023 May 15.
5
Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans.多基因自身免疫性疾病风险等位基因在小鼠和人类的共享分子网络中协同作用,影响 B 细胞耐受。
Front Immunol. 2022 Aug 24;13:953439. doi: 10.3389/fimmu.2022.953439. eCollection 2022.
6
Clinical and experimental treatment of type 1 diabetes.1 型糖尿病的临床和实验治疗。
Clin Exp Immunol. 2022 Dec 15;210(2):105-113. doi: 10.1093/cei/uxac077.
7
Personalized Immunotherapies for Type 1 Diabetes: Who, What, When, and How?1型糖尿病的个性化免疫疗法:对象、内容、时机及方式?
J Pers Med. 2022 Mar 29;12(4):542. doi: 10.3390/jpm12040542.
8
Intralymphatic GAD-alum Injection Modulates B Cell Response and Induces Follicular Helper T Cells and PD-1+ CD8+ T Cells in Patients With Recent-Onset Type 1 Diabetes.胰岛内注射 GAD 铝佐剂可调节胰岛炎患者的 B 细胞反应,并诱导滤泡辅助性 T 细胞和 PD-1+CD8+T 细胞
Front Immunol. 2022 Jan 12;12:797172. doi: 10.3389/fimmu.2021.797172. eCollection 2021.
9
Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes.1 型糖尿病中用于将生物标志物、机制和疾病结果联系起来的 T 细胞细胞测定标准化指南。
Eur J Immunol. 2022 Mar;52(3):372-388. doi: 10.1002/eji.202049067. Epub 2022 Jan 28.
10
Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity.深度免疫表型分析揭示衰老、唐氏综合征和自身免疫之间的相似性。
Sci Transl Med. 2022 Jan 12;14(627):eabi4888. doi: 10.1126/scitranslmed.abi4888.

本文引用的文献

1
Effector T Cell Resistance to Suppression and STAT3 Signaling during the Development of Human Type 1 Diabetes.在人类 1 型糖尿病的发展过程中,效应 T 细胞对抑制和 STAT3 信号的抵抗。
J Immunol. 2018 Aug 15;201(4):1144-1153. doi: 10.4049/jimmunol.1701199. Epub 2018 Jul 13.
2
Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.众志成城:提升 1 型糖尿病有效疗法研发机遇—— TrialNet 的经验。
Diabetes. 2018 Jul;67(7):1216-1225. doi: 10.2337/db18-0065. Epub 2018 May 16.
3
Loss of B-Cell Anergy in Type 1 Diabetes Is Associated With High-Risk HLA and Non-HLA Disease Susceptibility Alleles.1 型糖尿病中 B 细胞失能的丧失与高风险 HLA 和非 HLA 疾病易感性等位基因有关。
Diabetes. 2018 Apr;67(4):697-703. doi: 10.2337/db17-0937. Epub 2018 Jan 17.
4
Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state.1型糖尿病患者CD4记忆性T细胞中IL-2R信号传导减弱是内在的,且依赖于激活状态。
Clin Immunol. 2017 Aug;181:67-74. doi: 10.1016/j.clim.2017.06.004. Epub 2017 Jun 20.
5
Circulating CXCR5+PD-1+ICOS+ Follicular T Helper Cells Are Increased Close to the Diagnosis of Type 1 Diabetes in Children With Multiple Autoantibodies.在患有多种自身抗体的儿童中,循环CXCR5 + PD-1 + ICOS +滤泡辅助性T细胞在接近1型糖尿病诊断时会增加。
Diabetes. 2017 Feb;66(2):437-447. doi: 10.2337/db16-0714. Epub 2016 Oct 10.
6
PTPN22 inhibition resets defective human central B cell tolerance.蛋白酪氨酸磷酸酶非受体型22(PTPN22)抑制可重置有缺陷的人类中枢B细胞耐受性。
Sci Immunol. 2016;1(1). doi: 10.1126/sciimmunol.aaf7153. Epub 2016 Jul 22.
7
The BANK1 SLE-risk variants are associated with alterations in peripheral B cell signaling and development in humans.BANK1基因的系统性红斑狼疮风险变异与人类外周B细胞信号传导及发育的改变相关。
Clin Immunol. 2016 Dec;173:171-180. doi: 10.1016/j.clim.2016.10.018. Epub 2016 Nov 2.
8
Targeting B cells in treatment of autoimmunity.靶向B细胞治疗自身免疫性疾病。
Curr Opin Immunol. 2016 Dec;43:39-45. doi: 10.1016/j.coi.2016.09.003. Epub 2016 Oct 5.
9
Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.1型糖尿病中T细胞对白细胞介素-6的反应增强与早期临床疾病及白细胞介素-6受体表达增加有关。
Sci Transl Med. 2016 Sep 14;8(356):356ra119. doi: 10.1126/scitranslmed.aad9943.
10
Progress and challenges for treating Type 1 diabetes.治疗1型糖尿病的进展与挑战
J Autoimmun. 2016 Jul;71:1-9. doi: 10.1016/j.jaut.2016.04.004. Epub 2016 May 17.